Wave of Shareholder Lawsuits Continues
A number of publicly traded companies are facing new or pending securities class action lawsuits, reflecting heightened legal scrutiny in the markets. Law firms are actively soliciting investors in firms like Smart Digital Group, Aquestive Therapeutics, and Hub Group, among others, to join actions ahead of deadlines.
Securities class action filings saw a notable increase in 2024, continuing an upward trend from the previous year. This surge is largely attributed to a rise in cases alleging misleading statements under Section 10(b) of the Securities Exchange Act of 1934. The wave of litigation has particularly impacted the technology and healthcare sectors, which together accounted for more than half of all new federal securities class action lawsuits filed in 2024. A significant number of these cases have been filed in the Second and Ninth Circuits. A key driver of recent lawsuits has been the burgeoning field of artificial intelligence, with AI-related securities suits more than doubling in 2024 compared to the previous year. Conversely, litigation related to SPACs and cryptocurrencies, which saw a surge in previous years, has been on a downward trend. The allegations against the companies mentioned in the lawsuits are specific and varied. The case against Smart Digital Group, for instance, alleges a "market manipulation and fraudulent promotion scheme" involving misinformation on social media. In the case of Hub Group, the investigation centers on the company's announcement that it had understated transportation costs and would need to restate financial statements for the first three quarters of 2025. Aquestive Therapeutics is facing scrutiny over communications regarding the FDA approval process for its drug candidates. One lawsuit alleges the company made misleading statements about the approval likelihood of its drug Libervant, leading to a significant stock drop after the FDA issued a Complete Response Letter. A more recent investigation focuses on the company's disclosure of "deficiencies" in its New Drug Application for Anaphylm, which caused its stock to fall sharply. The financial repercussions of such lawsuits can be substantial. In 2024, the median settlement amount for securities class actions was $14 million, with the average settlement reaching $42.4 million. Beyond settlements, the initial announcement of a lawsuit can lead to an average stock price decline of 5%, and the reputational damage can have long-lasting effects on investor trust.
